Development of novel radiogallium-labeled bone imaging agents using oligo-aspartic acid peptides as carriers.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
    • Abstract:
      (68)Ga (T 1/2 = 68 min, a generator-produced nuclide) has great potential as a radionuclide for clinical positron emission tomography (PET). Because poly-glutamic and poly-aspartic acids have high affinity for hydroxyapatite, to develop new bone targeting (68)Ga-labeled bone imaging agents for PET, we used 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) as a chelating site and conjugated aspartic acid peptides of varying lengths. Subsequently, we compared Ga complexes, Ga-DOTA-(Asp)n (n = 2, 5, 8, 11, or 14) with easy-to-handle (67)Ga, with the previously described (67)Ga-DOTA complex conjugated bisphosphonate, (67)Ga-DOTA-Bn-SCN-HBP. After synthesizing DOTA-(Asp)n by a Fmoc-based solid-phase method, complexes were formed with (67)Ga, resulting in (67)Ga-DOTA-(Asp)n with a radiochemical purity of over 95% after HPLC purification. In hydroxyapatite binding assays, the binding rate of (67)Ga-DOTA-(Asp)n increased with the increase in the length of the conjugated aspartate peptide. Moreover, in biodistribution experiments, (67)Ga-DOTA-(Asp)8, (67)Ga-DOTA-(Asp)11, and (67)Ga-DOTA-(Asp)14 showed high accumulation in bone (10.5 ± 1.5, 15.1 ± 2.6, and 12.8 ± 1.7% ID/g, respectively) but were barely observed in other tissues at 60 min after injection. Although bone accumulation of (67)Ga-DOTA-(Asp)n was lower than that of (67)Ga-DOTA-Bn-SCN-HBP, blood clearance of (67)Ga-DOTA-(Asp)n was more rapid. Accordingly, the bone/blood ratios of (67)Ga-DOTA-(Asp)11 and (67)Ga-DOTA-(Asp)14 were comparable with those of (67)Ga-DOTA-Bn-SCN-HBP. In conclusion, these data provide useful insights into the drug design of (68)Ga-PET tracers for the diagnosis of bone disorders, such as bone metastases.
    • References:
      Breast Cancer Res Treat. 1994;32(1):73-84. (PMID: 7819589)
      Nucl Med Biol. 2006 May;33(4):513-20. (PMID: 16720243)
      Bioconjug Chem. 2005 Jul-Aug;16(4):751-7. (PMID: 16029015)
      Calcif Tissue Res. 1973 Dec 31;13(4):295-303. (PMID: 4788050)
      Bioconjug Chem. 2003 Sep-Oct;14(5):853-9. (PMID: 13129387)
      J Nucl Med. 1979 May;20(5):413-8. (PMID: 541698)
      Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):834. (PMID: 20069291)
      Eur J Nucl Med Mol Imaging. 2009 Nov;36(11):1807-12. (PMID: 19504092)
      Clin Nucl Med. 1980 Dec;5(12):565-8. (PMID: 6254718)
      J Med Chem. 2008 Feb 14;51(3):677-83. (PMID: 18181563)
      J Bone Miner Res. 2000 May;15(5):936-43. (PMID: 10804024)
      Int J Appl Radiat Isot. 1983 Dec;34(12):1577-84. (PMID: 6230322)
      Q J Nucl Med. 1999 Sep;43(3):259-67. (PMID: 10568141)
      J Drug Target. 2001 Apr;9(2):111-21. (PMID: 11697106)
      J Nucl Med. 1962 Jul;3:332-4. (PMID: 13869926)
      J Nucl Med. 2007 Oct;48(10):1741-8. (PMID: 17873136)
      J Nucl Med. 2006 Dec;47(12):2042-7. (PMID: 17138748)
      J Am Chem Soc. 2005 Nov 30;127(47):16477-85. (PMID: 16305234)
      Br J Radiol. 1989 Apr;62(736):318-20. (PMID: 2713589)
      J Nucl Med. 2007 Jan;48(1):122-7. (PMID: 17204708)
      Nucl Med Biol. 2011 Oct;38(7):1011-8. (PMID: 21982572)
      Connect Tissue Res. 1989;23(2-3):123-36. (PMID: 2698313)
      Nucl Med Biol. 2012 Oct;39(7):993-9. (PMID: 22633217)
      Bioconjug Chem. 2007 Sep-Oct;18(5):1375-8. (PMID: 17705416)
      J Biol Chem. 1988 Dec 25;263(36):19430-2. (PMID: 3198635)
      Tumori. 2005 Jan-Feb;91(1):77-80. (PMID: 15850010)
      Chem Commun (Camb). 2009 Aug 28;(32):4847-9. (PMID: 19652801)
      Bioconjug Chem. 2002 Jan-Feb;13(1):16-22. (PMID: 11792174)
      Bioconjug Chem. 2010 May 19;21(5):811-5. (PMID: 20387897)
      J Biol Inorg Chem. 2007 Jun;12(5):667-79. (PMID: 17333301)
      Nucl Med Biol. 2009 Feb;36(2):129-35. (PMID: 19217524)
      Endocrinology. 2001 Mar;142(3):1228-33. (PMID: 11181539)
      Nucl Med Biol. 2007 Jan;34(1):79-87. (PMID: 17210464)
      Anal Biochem. 1970 Apr;34(2):595-8. (PMID: 5443684)
      J Nucl Med. 1975 Aug;16(8):744-55. (PMID: 170385)
      Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):115-21. (PMID: 18709369)
      J Nucl Med. 2006 Feb;47(2):287-97. (PMID: 16455635)
      EJNMMI Res. 2012 Jun 09;2(1):28. (PMID: 22682112)
      Curr Med Chem. 2012;19(20):3290-300. (PMID: 22664247)
      EJNMMI Res. 2012 Mar 30;2(1):13. (PMID: 22464278)
      Nucl Med Biol. 2011 Jul;38(5):631-6. (PMID: 21718937)
      Radiographics. 2003 Mar-Apr;23(2):341-58. (PMID: 12640151)
      Int J Mol Imaging. 2011;2011:537687. (PMID: 22220275)
      Proc Natl Acad Sci U S A. 1986 Dec;83(23):8819-23. (PMID: 3024151)
      Br J Radiol. 1989 Apr;62(736):314-7. (PMID: 2713588)
      Radiology. 1980 Jul;136(1):209-11. (PMID: 6446106)
    • Accession Number:
      0 (Gallium Radioisotopes)
      0 (Heterocyclic Compounds, 1-Ring)
      0 (Peptides)
      1HTE449DGZ (1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid)
      26063-13-8 (polyaspartate)
      91D9GV0Z28 (Durapatite)
    • Publication Date:
      Date Created: 20140107 Date Completed: 20140902 Latest Revision: 20211021
    • Publication Date:
      20231215
    • Accession Number:
      PMC3877283
    • Accession Number:
      10.1371/journal.pone.0084335
    • Accession Number:
      24391942